Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)

被引：0
|
作者：
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Tan, Zhi
Carter, Brett W.
Zhang, Shuxing
Liu, Shengwu
Li, Shuai
Chen, Ting
Poteete, Alissa
Estrada-Bernal, Adriana
Le, Anh T.
Truini, Anna
Nilsson, Monique B.
Sun, Huiying
Roarty, Emily
Goldberg, Sarah B.
Brahmer, Julie R.
Altan, Mehmet
Lu, Charles
Papadimitrakopoulou, Vassiliki
Politi, Katerina
Doebele, Robert C.
Wong, Kwok-Kin
Heymach, John V.
机构：
[1] University of Texas MD Anderson Cancer Center,Department of Thoracic Head and Neck Medical Oncology
[2] University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
[3] University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology
[4] Dana-Farber Cancer Institute,Lowe Center for Thoracic Oncology
[5] University of Colorado Cancer Center,Yale Cancer Center
[6] Yale University School of Medicine,Department of Medicine
[7] Yale University School of Medicine,Sidney Kimmel Comprehensive Cancer Center
[8] Johns Hopkins University,Department of Pathology
[9] Yale University School of Medicine,Laura & Isaac Perlmutter Cancer Center
[10] New York University Langone Medical Center,undefined
来源：
NATURE MEDICINE | 2024年
关键词：
D O I：
10.1038/s41591-024-03178-1
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：2694 / 2695
页数：2
相关论文
共 50 条
  • [21] Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer
    Sacher, A.
    Le, X.
    Cornelissen, R.
    Shum, E.
    Suga, J.
    Socinski, M.
    Molina, J. R.
    Haura, E.
    Clarke, J.
    Bhat, G.
    Lebel, F.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S15 - S15
  • [22] Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Morita, Chie
    Yoshida, Tatsuya
    Shirasawa, Masayuki
    Masuda, Ken
    Matsumoto, Yuji
    Shinno, Yuki
    Yagishita, Shigehiro
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Motoi, Noriko
    Yatabe, Yasushi
    Ohe, Yuichiro
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
    Wang, Y.
    Jiang, T.
    Qin, Z.
    Jiang, J.
    Wang, Q.
    Yang, S.
    Rivard, C.
    Gao, G.
    Ng, T. L.
    Tu, M. M.
    Yu, H.
    Ji, H.
    Zhou, C.
    Ren, S.
    Zhang, J.
    Bunn, P.
    Doebele, R. C.
    Camidge, D. R.
    Hirsch, F. R.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 447 - 455
  • [24] Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
    Chie Morita
    Tatsuya Yoshida
    Masayuki Shirasawa
    Ken Masuda
    Yuji Matsumoto
    Yuki Shinno
    Shigehiro Yagishita
    Yusuke Okuma
    Yasushi Goto
    Hidehito Horinouchi
    Noboru Yamamoto
    Noriko Motoi
    Yasushi Yatabe
    Yuichiro Ohe
    Scientific Reports, 11
  • [25] Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients
    Garzon-Ibanez, Monica
    Reyes, Roxana
    Molina-Vila, Miguel Angel
    Sullivan, Ivana Gabriela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [26] Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells
    Moody, Terry W.
    Ramos-Alvarez, Irene
    Moreno, Paula
    Mantey, Samuel A.
    Ridnour, Lisa
    Wink, David
    Jensen, Robert T.
    PEPTIDES, 2017, 90 : 90 - 99
  • [27] Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
    Gao, X.
    Wei, X-W.
    Wu, Y-L.
    Zhou, Q.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] TY-4028: a novel, targeted therapy for non small-cell lung cancer with EGFR exon 20 or HER2 exon 20 insertion mutations
    Li, Jun
    Niu, Chengshan
    Guo, Zhongwei
    Wang, Huan
    Zheng, Bailu
    Dou, Yuge
    Liang, Apeng
    Ji, Kaige
    Dong, Shengli
    Li, Meihua
    Zhao, Yanchao
    Zhang, Yazhen
    Gong, Aishen
    Liu, Hao
    Hu, Xinmiao
    Su, Hui
    Jiang, Mingyu
    Chen, Shaoqing
    Chen, Xiugui
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [29] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    Signal Transduction and Targeted Therapy, 4
  • [30] Amivantamab with chemotherapy - Non-small cell lung cancer with EGFR exon 20 insertions
    Drappier, Noemie
    Pierret, Thomas
    BULLETIN DU CANCER, 2024, 111 (12) : 1085 - 1087
12345